The newly defined KRT14-eIF4H-ACOX2 axis orchestrates lipid metabolic reprogramming and cell survival, underscoring the KRT14-eIF4H interface as a promising therapeutic target for overcoming cisplatin resistance in BLCA. The gene discussed is EIF4H; the disease is bladder transitional cell carcinoma.